Three-Drug Tx Ups Survival in Light-Chain Amyloidosis

Share this content:
Three-Drug Tx Ups Survival in Light-Chain Amyloidosis
Three-Drug Tx Ups Survival in Light-Chain Amyloidosis

TUESDAY, June 21, 2016 (HealthDay News) -- For patients with heart failure due to light-chain amyloidosis (AL), three-drug therapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved survival, according to a study published in the June 28 issue of the Journal of the American College of Cardiology.

In a retrospective study, Brett W. Sperry, M.D., from the Cleveland Clinic Foundation, and colleagues examined the effect of BDex+AA as a first-line treatment strategy in patients with symptomatic heart failure from AL cardiac amyloidosis. Data were included for 106 treated patients, 40 of whom received the three-drug regimen and 66 of whom received other regimens. Survival was assessed after adjustment for the propensity score for receiving treatment, age, New York Heart Association functional class, and ejection fraction.

The researchers found that mortality was 65, 48, and 76 percent, respectively, overall, in the BDex+AA cohort, and in patients receiving other regimens. After multivariable adjustment, initial treatment with BDex+AA correlated with decreased mortality (hazard ratio, 0.209; P = 0.006). After further adjustment for components of the Mayo Stage the association persisted.

"Use of BDex+AA in the treatment of AL amyloidosis in patients presenting with symptomatic heart failure is associated with improved survival after adjusting for clinical variables," the authors write.

Two authors disclosed financial ties to pharmaceutical companies, including Takeda, the manufacturer of bortezomib.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

High Success Rates for Mitral Valve Repair With Robotic Surgery

High Success Rates for Mitral Valve Repair With ...

Minimally invasive surgery linked to fewer discharges to facility, one day less in hospital vs conservative sx

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Tattoo-Linked Complications ID'd in Immunosuppressed Female

Inflammatory myopathy identified in woman with cystic fibrosis on long-term immunosuppressants

Rates of Cardiac Stress Testing Down but Still Higher in CKD

Rates of Cardiac Stress Testing Down but Still ...

Decline in rates of cardiac stress testing in Medicare beneficiaries aged ≥66 years from 2008 to 2012

is free, fast, and customized just for you!




Already a member?

Sign In Now »